Sevoflurane
( DrugBank: Sevoflurane / KEGG DRUG: Sevoflurane )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
| 21 | Mitochondrial disease | 2 |
| 22 | Moyamoya disease | 3 |
| 34 | Neurofibromatosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastro-intestinal disorder | 1 |
| 225 | Congenital nephrogenic diabetes insipidus | 1 |
| 296 | Biliary atresia | 3 |
6. Parkinson disease
Clinical trials : 2,586 / Drugs : 1,871 - (DrugBank : 354) / Drug target genes : 188 - Drug target pathways : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
21. Mitochondrial disease
Clinical trials : 94 / Drugs : 75 - (DrugBank : 31) / Drug target genes : 51 - Drug target pathways : 106
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
22. Moyamoya disease
Clinical trials : 23 / Drugs : 29 - (DrugBank : 21) / Drug target genes : 35 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
34. Neurofibromatosis
Clinical trials : 165 / Drugs : 189 - (DrugBank : 83) / Drug target genes : 93 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
98. Eosinophilic gastro-intestinal disorder
Clinical trials : 214 / Drugs : 171 - (DrugBank : 46) / Drug target genes : 48 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
225. Congenital nephrogenic diabetes insipidus
Clinical trials : 17 / Drugs : 40 - (DrugBank : 19) / Drug target genes : 33 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
296. Biliary atresia
Clinical trials : 73 / Drugs : 67 - (DrugBank : 36) / Drug target genes : 51 - Drug target pathways : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|